| 1 | inc all rights reserved | | | | | | | 1 | 0.44% |
| 2 | innovation and capabilities to | | | | | | | 1 | 0.44% |
| 3 | disease to improve millions | | | | | | | 1 | 0.44% |
| 4 | to improve millions of | | | | | | | 1 | 0.44% |
| 5 | improve millions of lives | | | | | | | 1 | 0.44% |
| 6 | of lives throughout the world | | | | | | | 1 | 0.44% |
| 7 | the expertise innovation and | | | | | | | 1 | 0.44% |
| 8 | expertise innovation and capabilities | | | | | | | 1 | 0.44% |
| 9 | and capabilities to advance | | | | | | | 1 | 0.44% |
| 10 | and noncns indications by | | | | | | | 1 | 0.44% |
| 11 | capabilities to advance the | | | | | | | 1 | 0.44% |
| 12 | to advance the treatment | | | | | | | 1 | 0.44% |
| 13 | advance the treatment of | | | | | | | 1 | 0.44% |
| 14 | immunemediated and mitochondrial diseases | | | | | | | 1 | 0.44% |
| 15 | a portfolio of drug | | | | | | | 1 | 0.44% |
| 16 | portfolio of drug candidates | | | | | | | 1 | 0.44% |
| 17 | of drug candidates in | | | | | | | 1 | 0.44% |
| 18 | modifying disease to improve | | | | | | | 1 | 0.44% |
| 19 | cns and noncns indications | | | | | | | 1 | 0.44% |
| 20 | candidates in clinical and | | | | | | | 1 | 0.44% |
| 21 | we have the potential | | | | | | | 1 | 0.44% |
| 22 | candidates are master regulators | | | | | | | 1 | 0.44% |
| 23 | are master regulators of | | | | | | | 1 | 0.44% |
| 24 | master regulators of mitochondrial | | | | | | | 1 | 0.44% |
| 25 | regulators of mitochondrial and | | | | | | | 1 | 0.44% |
| 26 | lysosomal function we have | | | | | | | 1 | 0.44% |
| 27 | function we have the | | | | | | | 1 | 0.44% |
| 28 | have the potential to | | | | | | | 1 | 0.44% |
| 29 | of cns and noncns | | | | | | | 1 | 0.44% |
| 30 | the potential to revolutionize | | | | | | | 1 | 0.44% |
| 31 | potential to revolutionize the | | | | | | | 1 | 0.44% |
| 32 | management of an entire | | | | | | | 1 | 0.44% |
| 33 | of an entire range | | | | | | | 1 | 0.44% |
| 34 | an entire range of | | | | | | | 1 | 0.44% |
| 35 | entire range of cns | | | | | | | 1 | 0.44% |
| 36 | range of cns and | | | | | | | 1 | 0.44% |
| 37 | drug candidates in clinical | | | | | | | 1 | 0.44% |
| 38 | in clinical and preclinical | | | | | | | 1 | 0.44% |
| 39 | our therapeutic candidates are | | | | | | | 1 | 0.44% |
| 40 | for tqs168 for the | | | | | | | 1 | 0.44% |